CASVC logo

CASVC

Asia, Beijing, China, Beijing

Description

CASVC is investing in early and middle-term projects of cutting-edge technology.

Investor Profile

CASVC has made 4 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (25%)
  • Series B (25%)
  • Series C (25%)
  • Series E (25%)

Country Focus

  • China (100%)

Industry Focus

  • Fuel
  • Greentech
  • Sustainability
  • Biopharma
  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Communication Hardware
  • Communications Infrastructure
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does CASVC frequently co-invest with?

Daehwa Pharmaceutical
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Shanghai Lianhe Investment
Asia, Shanghai, China, Shanghai
Co-Investments: 1
CSPC Pharmaceutical Group
Asia, Hebei, China, Shijiazhuang
Co-Investments: 1
Atlas Capital LLC
North America, Arizona, United States, Phoenix
Co-Investments: 1
BioTrack Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
CAS Star
Asia, Hunan, China, Xian
Co-Investments: 1
Haitong Capital
Europe, Lisboa, Portugal, Lisbon
Co-Investments: 2

What are some of recent deals done by CASVC?

CAS New Intelligence

Tianjin, Guangdong, China

CAS New Intelligence engages in the development of medical devices like spectrometry instruments.

ManufacturingMedicalMedical Device
AngelApr 21, 2025
ICT Developer

Shanghai, Shanghai, China

ICT Developer is a domestic green and sustainable fuel company.

FuelGreenTechSustainability
Series ADec 30, 2024
Semight Instruments

Hangzhou, Zhejiang, China

Semight Instruments is a manufacturer that focuses on the optical communication module and chip test and measurement industry.

Communication HardwareCommunications InfrastructureElectronicsManufacturing
Series CApr 4, 2023
Wenge Group

Beijing, Beijing, China

Enterprise services company based in Beijing.

Enterprise
Series EOct 19, 2022
Amount Raised: $69,167,773
Haihe Biopharma

Shanghai, Shanghai, China

Haihe Biopharma is a biopharmaceutical company that develops cancer anti-tumour drugs.

BiopharmaBiotechnologyHealth CareMedicalPharmaceutical
Series BFeb 11, 2019
Amount Raised: $146,600,000